Title : A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens.

Pub. Date : 2010 Oct

PMID : 20802351






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Based on preclinical data and recent clinical observations, further development of AZD6244 in NSCLC should focus on BRAF or RAS mutation-positive patients and/or AZD6244-based combination regimens. AZD 6244 B-Raf proto-oncogene, serine/threonine kinase Homo sapiens